Document is current
Any future updates will be listed below
-
Authors
Gujarathi, Rushabh
Shergill, Ardaman
- License Information
-
More Information
Article History
Received: 18 December 2025
Accepted: 2 January 2026
First Online: 21 January 2026
Disclosure
: Ardaman Shergill has served in advisory and/or consultancy roles for Natera, Merus, Takeda, Ipson, Guardant, Pfizer, Amgen, Revolution Medicine, and Iterion Therapeutics; has received payment for research (to the institution) from Hutchison MediPharma/Takeda, Merck, Verastem Oncology, Turning Point Therapeutics, Gritstone, Bolt Therapeutics, BMS, Pfizer, Astellas, Oncologie, Macogenics, Seattle Genetics, Amgen, Daiichi, Eli Lilly, Jacobio, AstraZeneca, Genentech, Jazz Pharma, Agenus, and AbbVie; other payments for travel and speaking from the cure CRC Summit, Great Debates, OncLive, OSCO, ASCO, ACPMP, Cholangiocarcinoma Summit, Cholangiocarcinoma Foundation, ASCO Advantage; and payment from Takeda for an AACR poster.
